|
Press Release- 2014
Nes-Ziona, 15th Dec, 2014.Vaxil publishes the results of its Phase I/II study using ImMucin in Myeloma Patients in the "British Journal of Hematology".
For further details see the attached PDF file.
Nes-Ziona, 9th Nov, 2014.Vaxil has published a review article describing key advantages for its VaxHit technology.
For further details see the attached PDF file.
Nes-Ziona, 27th Jan, 2014.Vaxil is starting to treat the first patient with metastatic breast cancer using its therapeutic vaccine ImMucin.
For further details see the attached PDF file.
Nes-Ziona, 19th Jan, 2014.Vaxil utilizes its VaxHit technology to develop superior anti-MUC1 antibodies.
For further details see the attached PDF file.
|
|
